Let’s start up with the current stock price of Qualigen Therapeutics Inc. (QLGN), which is $1.94 to be very precise. The Stock rose vividly during the last session to $1.84 after opening rate of $1.76 while the lowest price it went was recorded $1.7243 before closing at $1.81.
Recently in News on July 14, 2021, Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19. Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Qualigen’s QN-165 with an initial target indication for the treatment of COVID-19 in hospitalized patients. QN-165, a DNA aptamer, is a broad-based antiviral drug candidate that has exhibited antiviral activity in multiple in vitro assays against different viruses. You can read further details here
Qualigen Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.4340 on 02/16/21, with the lowest value was $1.5100 for the same time period, recorded on 05/13/21.
Qualigen Therapeutics Inc. (QLGN) full year performance was -63.51%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Qualigen Therapeutics Inc. shares are logging -73.57% during the 52-week period from high price, and 28.48% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.51 and $7.34.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 848917 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Qualigen Therapeutics Inc. (QLGN) recorded performance in the market was -39.87%, having the revenues showcasing 0.00% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 51.86M, as it employees total of 34 workers.
Qualigen Therapeutics Inc. (QLGN) in the eye of market guru’s
During the last month, 0 analysts gave the Qualigen Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.2359, with a change in the price was noted -1.33. In a similar fashion, Qualigen Therapeutics Inc. posted a movement of -40.43% for the period of last 100 days, recording 659,747 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for QLGN is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Qualigen Therapeutics Inc. (QLGN): Stocks Technical analysis and Trends
Raw Stochastic average of Qualigen Therapeutics Inc. in the period of last 50 days is set at 53.57%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 59.65%. In the last 20 days, the company’s Stochastic %K was 36.84% and its Stochastic %D was recorded 22.19%.
If we look into the earlier routines of Qualigen Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -39.87%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -46.13%, alongside a downfall of -63.51% for the period of the last 12 months. The shares increased approximately by 1.69% in the 7-day charts and went up by -9.95% in the period of the last 30 days. Common stock shares were lifted by 0.00% during last recorded quarter.